Versant Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Versant Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-15	Closed	–	–	1441
2021 Q4	$0	Buy	+15	New	+$265	﹤0.01%	1423

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Versant Capital Management's ALLO Position: Q1 2022 in Review

Versant Capital Management sold out of Allogene Therapeutics (ALLO) in Q1 2022, closing a stake of 15 shares.

Versant Capital Management first reported a position in ALLO in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 180 funds tracked by Wall St. Rank hold ALLO as of Q1 2022.

Versant Capital Management reported no remaining Allogene Therapeutics position as of Q1 2022 after selling out during the quarter.
Versant Capital Management sold 15 Allogene Therapeutics shares in Q1 2022.
Versant Capital Management first reported a position in Allogene Therapeutics in Q4 2021 and held it in 1 quarter.
Versant Capital Management's Allogene Therapeutics position peaked at $0 in Q4 2021.
180 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2022.

Based on Versant Capital Management's 13F filing for Q1 2022, filed 29 Apr 2022.